Abstract: The present invention provides an artificial dressing and a use of the artificial dressing for promoting wound healing. The artificial dressing includes a gelatin and a fungal extract.

Abstract: Disclosed are controlled release particles, each controlled release particle of which includes: (a) a core including at least one hydrophobic active material and an emulsifier which is an oil-soluble or oil-dispersible lecithin emulsifier; and (b) a wall at least partially surrounding the core and including an acid insoluble polymer, a colloidal silica, a water insoluble divalent salt, a film forming polymer, and optionally a powder flow aid, wherein the controlled release particle is configured to retain the at least one hydrophobic active material when exposed to an acidic aqueous solution with a pH less than 6, and to release the at least one hydrophobic active material when exposed to a basic aqueous solution with a pH greater than 7. A method for preparing the particles and compositions containing the particles are also disclosed.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.

Abstract: The invention relates to a functional wound dressing being able to detect and indicate the state of the wound, in particular with regard to an infection which is reported to be frequently associated with poorly healing wounds, such as chronic wounds. The present wound dressing can be used in moist wound healing and contains a substance being able to absorb wound exudate from the wound and to provide moisture to the wound.

Abstract: Presented herein are compositions that can be administered to a subject having damaged tissue, for example a wound. The compositions are often administered in combination with administration of energy (e.g., laser energy, light from a light emitting diode, radiofrequency (RF) energy, audio frequency energy, etc.) from an energy generating device and/or system to the affected site. The compositions, systems, devices, and methods herein were found to induce wound healing and tissue regeneration.

Abstract: The invention relates to a functional wound dressing being able to provide substances supporting the healing of a wound to the wound depending on the condition of the wound. In particular, in case of an infection which is reported to be frequently associated with poorly healing wounds, such as chronic wounds, a therapeutic substance is provided to the wound whereas in other cases no therapeutic substance is provided. The present wound dressing can be used in moist wound healing and contains a substance being able to absorb wound exudate from the wound and to provide moisture to the wound.

Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Abstract: An adhesion-preventing material having a high adhesion-preventing effect has been demanded. An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.

Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Abstract: Provided is a novel bacterial strain Bacteroides vulgatus MGM001 (Bacteroides vulgatus MGM001) and its use. The LPS from the strain of the subject matter has cytotoxicity weaker than the conventional ones and shows synergistic effect on the inhibition of biofilm formation when used in combination with LTA.

Abstract: The present invention relates to a shear-thinning or pseudoplastic cosmetic composition. Zeta potentials may be balanced such that a first ratio of the first zeta potential to the second zeta potential may be approximately 1:2. A second ratio of the first zeta potential to the third zeta potential may be approximately 1:2. And, a third ratio of the second zeta potential to the third zeta potential may be approximately 1:1. Balancing zeta potentials may ensure the shear-thinning cosmetic composition can dispense in its original viscous form and as a fine mist through a single device.

Abstract: The present invention relates to a cosmetics composition having high anti-oxidant content. Specifically, the anti-oxidant of the present invention may be pure vitamin-C. More specifically, the present invention can maintain the potency of vitamin-C by preventing exposure of same to the outside air.

Abstract: A method of preparing a ginger water composition containing a ginger extract according to one embodiment of the present invention includes obtaining a ginger extract from a ginger root; mixing an organic solvent with the ginger extract; providing ultrasonic waves and obtaining a first solution; mixing water with the first solution; supplying heat and obtaining a second solution; and filtering the second solution.

Abstract: The present invention relates to a composition, preferably a cosmetic composition, and more preferably a skin cosmetic composition, comprising: (a) at least one particle, comprising at least one cationic polymer and at least one anionic polymer, at least one cationic polymer and at least one amphoteric polymer, at least one anionic polymer and at least one amphoteric polymer, or at least one amphoteric polymer, and at least one non-polymeric acid having two or more pKa values or salt(s) thereof or at least one non-polymeric base having two or more pKb values or salt(s) thereof; (b) at least one oil; and (c) water. The composition according to the present invention is stable, and can have a variety of cosmetic functions. For example, the composition according to the present invention can prepare a film which can have cosmetic effects such as moisturizing due to the oil(s).

Abstract: The present invention relates to interference pigments based on platelet-shaped substrates which are coated with at least four high refractive layers and to the use thereof, inter alia in paints, coatings, printings inks, plastics and in particular in cosmetic formulations. The interference pigments show a moderate chroma and can be used as effect pigments, as filler pigments and as protection agent against near infrared radiation, VIS and high energy light.

Abstract: An antimicrobial eyelid cleanser composition contains: (a) a hypohalous acid; (b) one or more surfactants having a HLB value of 5 to 18; and (c) an aqueous vehicle, the aqueous vehicle comprising: (i) one or more tonicity adjusters; (ii) one or more osmolality adjusters for adjusting an osmolality of the composition; and (iii) one or more pH adjusters for maintaining the pH of the composition at between about 4.5 to about 8.0. The composition can be dispensed in a foam, liquid, spray, mist, gel or lotion form. The composition can facilitate long term eyelid hygiene by removing excess oil, debris and desquamated skin and provide relief for inflammation of the eyes.

Abstract: The present invention relates to a topical composition comprising from 0.001 to 10% by weight a compound of formula (I), i.e. N-cyclopropyl nicotinamide, that provides improved antimicrobial effect through generation of antimicrobial peptides when applied to an external surface of the human body. A combination of compound of formula I and at least one ingredient selected from niacinamide, picolinamide and iso-nicotinamide triggers generation of AMPs in a synergistic way.

Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

Abstract: The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 ?g of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 ?m to 50 ?m. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.